Adrenal cancer diagnostics market to reach $206.14 billion by 2030

The Business Research Company projects the adrenal cancer diagnostics market will grow from $157.36 billion in 2026 to $206.14 billion by 2030, driven by imaging advances, targeted therapies and broader use of PET-CT scans. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - The adrenal cancer diagnostics market is expanding as clinicians rely more on imaging, biopsy techniques and specialized cancer centers to detect adrenal tumors earlier. - Faster diagnosis can improve treatment planning for adrenal cancer, which is critical because the disease is difficult to identify and manage. - The market outlook points to stronger demand for advanced diagnostic tools, especially as cancer awareness and funding increase.

What happened: - The Business Research Company released its Adrenal Cancer Diagnostics Global Market Report 2026 – Market Size, Trends, and Forecast 2026-2035. - The report estimates the market will rise from $148.54 billion in 2025 to $157.36 billion in 2026. - The report forecasts the market will reach $206.14 billion by 2030. - The report places North America as the largest regional market in 2025. - The report identifies Asia-Pacific as the fastest-growing region over the forecast period. - The full report is available here. - A free sample is available here.

The details: - The report says the market grew from limited availability of high-resolution imaging, rising adrenal tumor prevalence, greater awareness of adrenal cancer, continued dependence on conventional biopsy techniques and hospital infrastructure development. - The forecast calls for a 5.9% CAGR from 2025 to 2026. - The report projects a 7.0% CAGR from 2026 to 2030. - Expected growth drivers include contrast-enhanced imaging technologies, targeted adrenal cancer therapies, PET-CT combination scans, specialized cancer centers and government funding for cancer diagnostics. - Expected trends include wider use of advanced imaging, more minimally invasive biopsy methods, growth in targeted therapeutic applications, expansion of multidisciplinary diagnostic centers and more emphasis on early detection and personalized treatment plans. - Adrenal cancer diagnostics refers to the medical process used to detect cancer in the adrenal glands, which sit above the kidneys. - Accurate diagnosis is essential for planning effective treatment and managing the disease.

Between the lines: - The report links market growth to smoking, citing tobacco smoke as a risk factor for adrenal cancers including adrenal adenomas and adrenocortical carcinomas. - The report says carcinogens in cigarette smoke can damage adrenal-cell DNA and trigger mutations that lead to cancer. - Statistics Canada reported in August 2024 that Canadian manufacturers produced 1.2 billion cigarettes in July 2024, up 4.3% from June 2024 and 2.3% from July 2023. - The smoking data is being used as a proxy for rising exposure that could support demand for diagnostics, rather than as direct proof of market demand.

What's next: - The market is expected to benefit from broader adoption of PET-CT scans and advanced imaging methods. - More diagnostic centers are likely to adopt minimally invasive biopsy approaches and multidisciplinary workflows. - Government support for cancer diagnostics could further accelerate demand through 2030. - The report also adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspots infographics and updated graphics for 2026.

The bottom line: - Adrenal cancer diagnostics is moving from a niche market story to a broader growth play tied to imaging innovation, cancer awareness and earlier detection.